nodes	percent_of_prediction	percent_of_DWPC	metapath
Sitaxentan—CYP3A4—bone cancer	0.738	1	CbGaD
Sitaxentan—EDNRB—Endothelins—GNA11—bone cancer	0.00137	0.0408	CbGpPWpGaD
Sitaxentan—EDNRA—EGFR-dependent Endothelin signaling events—EGFR—bone cancer	0.00132	0.0395	CbGpPWpGaD
Sitaxentan—EDNRA—GPCRs, Other—GRM1—bone cancer	0.00113	0.0338	CbGpPWpGaD
Sitaxentan—CYP2C19—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00109	0.0324	CbGpPWpGaD
Sitaxentan—EDNRB—Prostaglandin Synthesis and Regulation—PTGS2—bone cancer	0.000996	0.0297	CbGpPWpGaD
Sitaxentan—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000992	0.0296	CbGpPWpGaD
Sitaxentan—EDNRA—Endothelins—GNA11—bone cancer	0.00098	0.0292	CbGpPWpGaD
Sitaxentan—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.000949	0.0283	CbGpPWpGaD
Sitaxentan—EDNRB—G alpha (q) signalling events—GRM1—bone cancer	0.00089	0.0265	CbGpPWpGaD
Sitaxentan—EDNRA—GPCRs, Other—SMO—bone cancer	0.000799	0.0238	CbGpPWpGaD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—GRM1—bone cancer	0.000796	0.0237	CbGpPWpGaD
Sitaxentan—EDNRA—Prostaglandin Synthesis and Regulation—PTGS2—bone cancer	0.000713	0.0212	CbGpPWpGaD
Sitaxentan—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000654	0.0195	CbGpPWpGaD
Sitaxentan—EDNRA—G alpha (q) signalling events—GRM1—bone cancer	0.000637	0.019	CbGpPWpGaD
Sitaxentan—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000616	0.0183	CbGpPWpGaD
Sitaxentan—EDNRB—G alpha (q) signalling events—GNA11—bone cancer	0.000574	0.0171	CbGpPWpGaD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—GRM1—bone cancer	0.00057	0.017	CbGpPWpGaD
Sitaxentan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000536	0.016	CbGpPWpGaD
Sitaxentan—CYP2C19—Xenobiotics—CYP3A4—bone cancer	0.000525	0.0157	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—GRM4—bone cancer	0.000518	0.0154	CbGpPWpGaD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	0.000513	0.0153	CbGpPWpGaD
Sitaxentan—CYP2C19—Tamoxifen metabolism—CYP3A4—bone cancer	0.000505	0.0151	CbGpPWpGaD
Sitaxentan—EDNRB—Endothelins—JUN—bone cancer	0.000496	0.0148	CbGpPWpGaD
Sitaxentan—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.000479	0.0143	CbGpPWpGaD
Sitaxentan—CYP2C19—Metapathway biotransformation—CYP4V2—bone cancer	0.000468	0.014	CbGpPWpGaD
Sitaxentan—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.000461	0.0137	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—GRM1—bone cancer	0.000449	0.0134	CbGpPWpGaD
Sitaxentan—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.000427	0.0127	CbGpPWpGaD
Sitaxentan—EDNRA—G alpha (q) signalling events—GNA11—bone cancer	0.000411	0.0122	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—GRM4—bone cancer	0.000371	0.011	CbGpPWpGaD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	0.000367	0.0109	CbGpPWpGaD
Sitaxentan—CYP2C19—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000361	0.0107	CbGpPWpGaD
Sitaxentan—EDNRA—Endothelins—JUN—bone cancer	0.000355	0.0106	CbGpPWpGaD
Sitaxentan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000354	0.0105	CbGpPWpGaD
Sitaxentan—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000329	0.0098	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—GRM1—bone cancer	0.000321	0.00958	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—SMO—bone cancer	0.000316	0.00943	CbGpPWpGaD
Sitaxentan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000313	0.00933	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—RGS1—bone cancer	0.000293	0.00872	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—GRM4—bone cancer	0.000293	0.00872	CbGpPWpGaD
Sitaxentan—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000282	0.00839	CbGpPWpGaD
Sitaxentan—Aspartate aminotransferase increased—Epirubicin—bone cancer	0.000275	0.00121	CcSEcCtD
Sitaxentan—Hypotension—Cisplatin—bone cancer	0.000273	0.0012	CcSEcCtD
Sitaxentan—Abdominal discomfort—Methotrexate—bone cancer	0.00027	0.00119	CcSEcCtD
Sitaxentan—Muscular weakness—Epirubicin—bone cancer	0.000269	0.00118	CcSEcCtD
Sitaxentan—Alanine aminotransferase increased—Epirubicin—bone cancer	0.000269	0.00118	CcSEcCtD
Sitaxentan—Pancytopenia—Methotrexate—bone cancer	0.000268	0.00117	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—RGS1—bone cancer	0.000266	0.00792	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—GRM4—bone cancer	0.000266	0.00792	CbGpPWpGaD
Sitaxentan—Ataxia—Doxorubicin—bone cancer	0.000266	0.00117	CcSEcCtD
Sitaxentan—Blood creatinine increased—Doxorubicin—bone cancer	0.000265	0.00116	CcSEcCtD
Sitaxentan—Asthma—Epirubicin—bone cancer	0.000264	0.00116	CcSEcCtD
Sitaxentan—Dysuria—Methotrexate—bone cancer	0.000264	0.00116	CcSEcCtD
Sitaxentan—Dehydration—Doxorubicin—bone cancer	0.000263	0.00115	CcSEcCtD
Sitaxentan—Eosinophilia—Epirubicin—bone cancer	0.000261	0.00115	CcSEcCtD
Sitaxentan—Liver function test abnormal—Doxorubicin—bone cancer	0.000261	0.00114	CcSEcCtD
Sitaxentan—Dry skin—Doxorubicin—bone cancer	0.000259	0.00114	CcSEcCtD
Sitaxentan—Orthostatic hypotension—Doxorubicin—bone cancer	0.000258	0.00113	CcSEcCtD
Sitaxentan—Abdominal pain upper—Doxorubicin—bone cancer	0.000258	0.00113	CcSEcCtD
Sitaxentan—Photosensitivity reaction—Methotrexate—bone cancer	0.000257	0.00113	CcSEcCtD
Sitaxentan—Angina pectoris—Epirubicin—bone cancer	0.000257	0.00113	CcSEcCtD
Sitaxentan—Breast disorder—Doxorubicin—bone cancer	0.000255	0.00112	CcSEcCtD
Sitaxentan—Aspartate aminotransferase increased—Doxorubicin—bone cancer	0.000254	0.00112	CcSEcCtD
Sitaxentan—Decreased appetite—Cisplatin—bone cancer	0.000254	0.00111	CcSEcCtD
Sitaxentan—Bronchitis—Epirubicin—bone cancer	0.000254	0.00111	CcSEcCtD
Sitaxentan—EDNRB—GPCR downstream signaling—GRM1—bone cancer	0.000254	0.00756	CbGpPWpGaD
Sitaxentan—Gastrointestinal disorder—Cisplatin—bone cancer	0.000252	0.00111	CcSEcCtD
Sitaxentan—Infestation NOS—Methotrexate—bone cancer	0.000251	0.0011	CcSEcCtD
Sitaxentan—Infestation—Methotrexate—bone cancer	0.000251	0.0011	CcSEcCtD
Sitaxentan—Pancytopenia—Epirubicin—bone cancer	0.000251	0.0011	CcSEcCtD
Sitaxentan—Pain—Cisplatin—bone cancer	0.00025	0.0011	CcSEcCtD
Sitaxentan—Muscular weakness—Doxorubicin—bone cancer	0.000249	0.00109	CcSEcCtD
Sitaxentan—Alanine aminotransferase increased—Doxorubicin—bone cancer	0.000249	0.00109	CcSEcCtD
Sitaxentan—Renal failure—Methotrexate—bone cancer	0.000247	0.00108	CcSEcCtD
Sitaxentan—Dysuria—Epirubicin—bone cancer	0.000247	0.00108	CcSEcCtD
Sitaxentan—Stomatitis—Methotrexate—bone cancer	0.000245	0.00107	CcSEcCtD
Sitaxentan—Conjunctivitis—Methotrexate—bone cancer	0.000244	0.00107	CcSEcCtD
Sitaxentan—Asthma—Doxorubicin—bone cancer	0.000244	0.00107	CcSEcCtD
Sitaxentan—Pollakiuria—Epirubicin—bone cancer	0.000244	0.00107	CcSEcCtD
Sitaxentan—Eosinophilia—Doxorubicin—bone cancer	0.000242	0.00106	CcSEcCtD
Sitaxentan—Photosensitivity reaction—Epirubicin—bone cancer	0.000241	0.00106	CcSEcCtD
Sitaxentan—Feeling abnormal—Cisplatin—bone cancer	0.000241	0.00106	CcSEcCtD
Sitaxentan—Haematuria—Methotrexate—bone cancer	0.00024	0.00105	CcSEcCtD
Sitaxentan—Weight decreased—Epirubicin—bone cancer	0.000239	0.00105	CcSEcCtD
Sitaxentan—Hyperglycaemia—Epirubicin—bone cancer	0.000238	0.00104	CcSEcCtD
Sitaxentan—Angina pectoris—Doxorubicin—bone cancer	0.000238	0.00104	CcSEcCtD
Sitaxentan—Hepatobiliary disease—Methotrexate—bone cancer	0.000238	0.00104	CcSEcCtD
Sitaxentan—Epistaxis—Methotrexate—bone cancer	0.000237	0.00104	CcSEcCtD
Sitaxentan—Infestation—Epirubicin—bone cancer	0.000235	0.00103	CcSEcCtD
Sitaxentan—Infestation NOS—Epirubicin—bone cancer	0.000235	0.00103	CcSEcCtD
Sitaxentan—Bronchitis—Doxorubicin—bone cancer	0.000235	0.00103	CcSEcCtD
Sitaxentan—Pancytopenia—Doxorubicin—bone cancer	0.000232	0.00102	CcSEcCtD
Sitaxentan—Renal failure—Epirubicin—bone cancer	0.000231	0.00101	CcSEcCtD
Sitaxentan—Body temperature increased—Cisplatin—bone cancer	0.000231	0.00101	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—GRM1—bone cancer	0.00023	0.00687	CbGpPWpGaD
Sitaxentan—Jaundice—Epirubicin—bone cancer	0.000229	0.00101	CcSEcCtD
Sitaxentan—Stomatitis—Epirubicin—bone cancer	0.000229	0.00101	CcSEcCtD
Sitaxentan—Conjunctivitis—Epirubicin—bone cancer	0.000229	0.001	CcSEcCtD
Sitaxentan—Dysuria—Doxorubicin—bone cancer	0.000228	0.001	CcSEcCtD
Sitaxentan—Haemoglobin—Methotrexate—bone cancer	0.000227	0.000995	CcSEcCtD
Sitaxentan—EDNRA—GPCR ligand binding—SMO—bone cancer	0.000226	0.00675	CbGpPWpGaD
Sitaxentan—Haemorrhage—Methotrexate—bone cancer	0.000226	0.00099	CcSEcCtD
Sitaxentan—Hepatitis—Methotrexate—bone cancer	0.000226	0.00099	CcSEcCtD
Sitaxentan—Pollakiuria—Doxorubicin—bone cancer	0.000226	0.000989	CcSEcCtD
Sitaxentan—Haematuria—Epirubicin—bone cancer	0.000224	0.000984	CcSEcCtD
Sitaxentan—Urinary tract disorder—Methotrexate—bone cancer	0.000223	0.000978	CcSEcCtD
Sitaxentan—Photosensitivity reaction—Doxorubicin—bone cancer	0.000223	0.000978	CcSEcCtD
Sitaxentan—Hepatobiliary disease—Epirubicin—bone cancer	0.000223	0.000976	CcSEcCtD
Sitaxentan—Epistaxis—Epirubicin—bone cancer	0.000222	0.000973	CcSEcCtD
Sitaxentan—Urethral disorder—Methotrexate—bone cancer	0.000221	0.00097	CcSEcCtD
Sitaxentan—Weight decreased—Doxorubicin—bone cancer	0.000221	0.000969	CcSEcCtD
Sitaxentan—Sinusitis—Epirubicin—bone cancer	0.000221	0.000968	CcSEcCtD
Sitaxentan—Hyperglycaemia—Doxorubicin—bone cancer	0.00022	0.000966	CcSEcCtD
Sitaxentan—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000218	0.0065	CbGpPWpGaD
Sitaxentan—Infestation NOS—Doxorubicin—bone cancer	0.000218	0.000955	CcSEcCtD
Sitaxentan—Infestation—Doxorubicin—bone cancer	0.000218	0.000955	CcSEcCtD
Sitaxentan—Visual impairment—Methotrexate—bone cancer	0.000218	0.000954	CcSEcCtD
Sitaxentan—Hypersensitivity—Cisplatin—bone cancer	0.000215	0.000944	CcSEcCtD
Sitaxentan—CYP2C19—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000215	0.00641	CbGpPWpGaD
Sitaxentan—Bradycardia—Epirubicin—bone cancer	0.000215	0.000943	CcSEcCtD
Sitaxentan—Renal failure—Doxorubicin—bone cancer	0.000214	0.000939	CcSEcCtD
Sitaxentan—Haemoglobin—Epirubicin—bone cancer	0.000212	0.000931	CcSEcCtD
Sitaxentan—Jaundice—Doxorubicin—bone cancer	0.000212	0.000931	CcSEcCtD
Sitaxentan—Stomatitis—Doxorubicin—bone cancer	0.000212	0.000931	CcSEcCtD
Sitaxentan—Rhinitis—Epirubicin—bone cancer	0.000212	0.000929	CcSEcCtD
Sitaxentan—Conjunctivitis—Doxorubicin—bone cancer	0.000212	0.000928	CcSEcCtD
Sitaxentan—Haemorrhage—Epirubicin—bone cancer	0.000211	0.000926	CcSEcCtD
Sitaxentan—Hepatitis—Epirubicin—bone cancer	0.000211	0.000926	CcSEcCtD
Sitaxentan—Eye disorder—Methotrexate—bone cancer	0.000211	0.000925	CcSEcCtD
Sitaxentan—Tinnitus—Methotrexate—bone cancer	0.00021	0.000923	CcSEcCtD
Sitaxentan—Asthenia—Cisplatin—bone cancer	0.00021	0.00092	CcSEcCtD
Sitaxentan—Cardiac disorder—Methotrexate—bone cancer	0.000209	0.000919	CcSEcCtD
Sitaxentan—EDNRA—GPCR downstream signaling—RGS1—bone cancer	0.000209	0.00624	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—GRM4—bone cancer	0.000209	0.00624	CbGpPWpGaD
Sitaxentan—Urinary tract disorder—Epirubicin—bone cancer	0.000209	0.000915	CcSEcCtD
Sitaxentan—Oedema peripheral—Epirubicin—bone cancer	0.000208	0.000913	CcSEcCtD
Sitaxentan—Haematuria—Doxorubicin—bone cancer	0.000208	0.00091	CcSEcCtD
Sitaxentan—Urethral disorder—Epirubicin—bone cancer	0.000207	0.000908	CcSEcCtD
Sitaxentan—Hepatobiliary disease—Doxorubicin—bone cancer	0.000206	0.000903	CcSEcCtD
Sitaxentan—Epistaxis—Doxorubicin—bone cancer	0.000205	0.000901	CcSEcCtD
Sitaxentan—Angiopathy—Methotrexate—bone cancer	0.000205	0.000898	CcSEcCtD
Sitaxentan—Sinusitis—Doxorubicin—bone cancer	0.000204	0.000896	CcSEcCtD
Sitaxentan—Immune system disorder—Methotrexate—bone cancer	0.000204	0.000894	CcSEcCtD
Sitaxentan—Visual impairment—Epirubicin—bone cancer	0.000204	0.000893	CcSEcCtD
Sitaxentan—Mediastinal disorder—Methotrexate—bone cancer	0.000203	0.000892	CcSEcCtD
Sitaxentan—Diarrhoea—Cisplatin—bone cancer	0.0002	0.000877	CcSEcCtD
Sitaxentan—Alopecia—Methotrexate—bone cancer	0.000199	0.000875	CcSEcCtD
Sitaxentan—Bradycardia—Doxorubicin—bone cancer	0.000199	0.000873	CcSEcCtD
Sitaxentan—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000199	0.00593	CbGpPWpGaD
Sitaxentan—Mental disorder—Methotrexate—bone cancer	0.000198	0.000867	CcSEcCtD
Sitaxentan—Eye disorder—Epirubicin—bone cancer	0.000197	0.000866	CcSEcCtD
Sitaxentan—Tinnitus—Epirubicin—bone cancer	0.000197	0.000864	CcSEcCtD
Sitaxentan—Malnutrition—Methotrexate—bone cancer	0.000197	0.000862	CcSEcCtD
Sitaxentan—Haemoglobin—Doxorubicin—bone cancer	0.000196	0.000862	CcSEcCtD
Sitaxentan—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000196	0.00585	CbGpPWpGaD
Sitaxentan—Cardiac disorder—Epirubicin—bone cancer	0.000196	0.00086	CcSEcCtD
Sitaxentan—Flushing—Epirubicin—bone cancer	0.000196	0.00086	CcSEcCtD
Sitaxentan—Rhinitis—Doxorubicin—bone cancer	0.000196	0.000859	CcSEcCtD
Sitaxentan—Haemorrhage—Doxorubicin—bone cancer	0.000195	0.000857	CcSEcCtD
Sitaxentan—Hepatitis—Doxorubicin—bone cancer	0.000195	0.000857	CcSEcCtD
Sitaxentan—Urinary tract disorder—Doxorubicin—bone cancer	0.000193	0.000847	CcSEcCtD
Sitaxentan—Oedema peripheral—Doxorubicin—bone cancer	0.000193	0.000844	CcSEcCtD
Sitaxentan—Angiopathy—Epirubicin—bone cancer	0.000192	0.000841	CcSEcCtD
Sitaxentan—Urethral disorder—Doxorubicin—bone cancer	0.000192	0.00084	CcSEcCtD
Sitaxentan—Immune system disorder—Epirubicin—bone cancer	0.000191	0.000837	CcSEcCtD
Sitaxentan—Mediastinal disorder—Epirubicin—bone cancer	0.00019	0.000835	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—RGS1—bone cancer	0.00019	0.00567	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—GRM4—bone cancer	0.00019	0.00567	CbGpPWpGaD
Sitaxentan—Visual impairment—Doxorubicin—bone cancer	0.000188	0.000826	CcSEcCtD
Sitaxentan—Alopecia—Epirubicin—bone cancer	0.000187	0.000819	CcSEcCtD
Sitaxentan—Vomiting—Cisplatin—bone cancer	0.000186	0.000815	CcSEcCtD
Sitaxentan—Mental disorder—Epirubicin—bone cancer	0.000185	0.000812	CcSEcCtD
Sitaxentan—Rash—Cisplatin—bone cancer	0.000184	0.000808	CcSEcCtD
Sitaxentan—Dermatitis—Cisplatin—bone cancer	0.000184	0.000807	CcSEcCtD
Sitaxentan—Malnutrition—Epirubicin—bone cancer	0.000184	0.000806	CcSEcCtD
Sitaxentan—Eye disorder—Doxorubicin—bone cancer	0.000183	0.000801	CcSEcCtD
Sitaxentan—Ill-defined disorder—Methotrexate—bone cancer	0.000182	0.0008	CcSEcCtD
Sitaxentan—Tinnitus—Doxorubicin—bone cancer	0.000182	0.000799	CcSEcCtD
Sitaxentan—Anaemia—Methotrexate—bone cancer	0.000182	0.000797	CcSEcCtD
Sitaxentan—EDNRA—GPCR downstream signaling—GRM1—bone cancer	0.000182	0.00541	CbGpPWpGaD
Sitaxentan—Flushing—Doxorubicin—bone cancer	0.000181	0.000796	CcSEcCtD
Sitaxentan—Cardiac disorder—Doxorubicin—bone cancer	0.000181	0.000796	CcSEcCtD
Sitaxentan—Tension—Epirubicin—bone cancer	0.00018	0.000791	CcSEcCtD
Sitaxentan—Nervousness—Epirubicin—bone cancer	0.000179	0.000783	CcSEcCtD
Sitaxentan—Angiopathy—Doxorubicin—bone cancer	0.000177	0.000778	CcSEcCtD
Sitaxentan—Malaise—Methotrexate—bone cancer	0.000177	0.000777	CcSEcCtD
Sitaxentan—Muscle spasms—Epirubicin—bone cancer	0.000177	0.000775	CcSEcCtD
Sitaxentan—CYP2C19—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000177	0.00527	CbGpPWpGaD
Sitaxentan—Immune system disorder—Doxorubicin—bone cancer	0.000177	0.000774	CcSEcCtD
Sitaxentan—Vertigo—Methotrexate—bone cancer	0.000177	0.000774	CcSEcCtD
Sitaxentan—Mediastinal disorder—Doxorubicin—bone cancer	0.000176	0.000773	CcSEcCtD
Sitaxentan—Leukopenia—Methotrexate—bone cancer	0.000176	0.000771	CcSEcCtD
Sitaxentan—Nausea—Cisplatin—bone cancer	0.000174	0.000761	CcSEcCtD
Sitaxentan—Alopecia—Doxorubicin—bone cancer	0.000173	0.000758	CcSEcCtD
Sitaxentan—Mental disorder—Doxorubicin—bone cancer	0.000171	0.000751	CcSEcCtD
Sitaxentan—Ill-defined disorder—Epirubicin—bone cancer	0.000171	0.000748	CcSEcCtD
Sitaxentan—Malnutrition—Doxorubicin—bone cancer	0.00017	0.000746	CcSEcCtD
Sitaxentan—Anaemia—Epirubicin—bone cancer	0.00017	0.000745	CcSEcCtD
Sitaxentan—Agitation—Epirubicin—bone cancer	0.000169	0.000741	CcSEcCtD
Sitaxentan—Chest pain—Methotrexate—bone cancer	0.000167	0.000734	CcSEcCtD
Sitaxentan—Tension—Doxorubicin—bone cancer	0.000167	0.000732	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000166	0.000729	CcSEcCtD
Sitaxentan—Malaise—Epirubicin—bone cancer	0.000166	0.000727	CcSEcCtD
Sitaxentan—Discomfort—Methotrexate—bone cancer	0.000165	0.000725	CcSEcCtD
Sitaxentan—Nervousness—Doxorubicin—bone cancer	0.000165	0.000725	CcSEcCtD
Sitaxentan—Vertigo—Epirubicin—bone cancer	0.000165	0.000725	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—GRM1—bone cancer	0.000165	0.00491	CbGpPWpGaD
Sitaxentan—Leukopenia—Epirubicin—bone cancer	0.000165	0.000722	CcSEcCtD
Sitaxentan—Muscle spasms—Doxorubicin—bone cancer	0.000164	0.000717	CcSEcCtD
Sitaxentan—EDNRB—GPCR downstream signaling—GNA11—bone cancer	0.000164	0.00487	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—SMO—bone cancer	0.000162	0.00484	CbGpPWpGaD
Sitaxentan—Confusional state—Methotrexate—bone cancer	0.000162	0.000709	CcSEcCtD
Sitaxentan—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000161	0.0048	CbGpPWpGaD
Sitaxentan—Infection—Methotrexate—bone cancer	0.000159	0.000699	CcSEcCtD
Sitaxentan—Ill-defined disorder—Doxorubicin—bone cancer	0.000158	0.000692	CcSEcCtD
Sitaxentan—Nervous system disorder—Methotrexate—bone cancer	0.000157	0.00069	CcSEcCtD
Sitaxentan—Anaemia—Doxorubicin—bone cancer	0.000157	0.00069	CcSEcCtD
Sitaxentan—Thrombocytopenia—Methotrexate—bone cancer	0.000157	0.000689	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—RGS1—bone cancer	0.000157	0.00468	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—GRM4—bone cancer	0.000157	0.00468	CbGpPWpGaD
Sitaxentan—Chest pain—Epirubicin—bone cancer	0.000157	0.000687	CcSEcCtD
Sitaxentan—Agitation—Doxorubicin—bone cancer	0.000156	0.000686	CcSEcCtD
Sitaxentan—Skin disorder—Methotrexate—bone cancer	0.000156	0.000683	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000155	0.000682	CcSEcCtD
Sitaxentan—Discomfort—Epirubicin—bone cancer	0.000155	0.000678	CcSEcCtD
Sitaxentan—Malaise—Doxorubicin—bone cancer	0.000153	0.000673	CcSEcCtD
Sitaxentan—Dry mouth—Epirubicin—bone cancer	0.000153	0.000672	CcSEcCtD
Sitaxentan—Vertigo—Doxorubicin—bone cancer	0.000153	0.00067	CcSEcCtD
Sitaxentan—Anorexia—Methotrexate—bone cancer	0.000153	0.00067	CcSEcCtD
Sitaxentan—Leukopenia—Doxorubicin—bone cancer	0.000152	0.000668	CcSEcCtD
Sitaxentan—Confusional state—Epirubicin—bone cancer	0.000151	0.000664	CcSEcCtD
Sitaxentan—Oedema—Epirubicin—bone cancer	0.00015	0.000658	CcSEcCtD
Sitaxentan—Hypotension—Methotrexate—bone cancer	0.00015	0.000657	CcSEcCtD
Sitaxentan—Infection—Epirubicin—bone cancer	0.000149	0.000654	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—GNA11—bone cancer	0.000148	0.00442	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—IL3—bone cancer	0.000148	0.00442	CbGpPWpGaD
Sitaxentan—Nervous system disorder—Epirubicin—bone cancer	0.000147	0.000645	CcSEcCtD
Sitaxentan—Thrombocytopenia—Epirubicin—bone cancer	0.000147	0.000644	CcSEcCtD
Sitaxentan—Tachycardia—Epirubicin—bone cancer	0.000146	0.000642	CcSEcCtD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	0.000146	0.00435	CbGpPWpGaD
Sitaxentan—Skin disorder—Epirubicin—bone cancer	0.000146	0.000639	CcSEcCtD
Sitaxentan—Insomnia—Methotrexate—bone cancer	0.000145	0.000636	CcSEcCtD
Sitaxentan—Chest pain—Doxorubicin—bone cancer	0.000145	0.000635	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000144	0.000631	CcSEcCtD
Sitaxentan—Discomfort—Doxorubicin—bone cancer	0.000143	0.000628	CcSEcCtD
Sitaxentan—Anorexia—Epirubicin—bone cancer	0.000143	0.000627	CcSEcCtD
Sitaxentan—Somnolence—Methotrexate—bone cancer	0.000143	0.000625	CcSEcCtD
Sitaxentan—Dry mouth—Doxorubicin—bone cancer	0.000142	0.000621	CcSEcCtD
Sitaxentan—Dyspepsia—Methotrexate—bone cancer	0.000141	0.000619	CcSEcCtD
Sitaxentan—Hypotension—Epirubicin—bone cancer	0.00014	0.000615	CcSEcCtD
Sitaxentan—Confusional state—Doxorubicin—bone cancer	0.00014	0.000614	CcSEcCtD
Sitaxentan—Decreased appetite—Methotrexate—bone cancer	0.000139	0.000611	CcSEcCtD
Sitaxentan—Oedema—Doxorubicin—bone cancer	0.000139	0.000609	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Methotrexate—bone cancer	0.000138	0.000607	CcSEcCtD
Sitaxentan—Fatigue—Methotrexate—bone cancer	0.000138	0.000606	CcSEcCtD
Sitaxentan—Infection—Doxorubicin—bone cancer	0.000138	0.000605	CcSEcCtD
Sitaxentan—Pain—Methotrexate—bone cancer	0.000137	0.000601	CcSEcCtD
Sitaxentan—Nervous system disorder—Doxorubicin—bone cancer	0.000136	0.000597	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—GRM1—bone cancer	0.000136	0.00406	CbGpPWpGaD
Sitaxentan—Thrombocytopenia—Doxorubicin—bone cancer	0.000136	0.000596	CcSEcCtD
Sitaxentan—Insomnia—Epirubicin—bone cancer	0.000136	0.000595	CcSEcCtD
Sitaxentan—Tachycardia—Doxorubicin—bone cancer	0.000136	0.000594	CcSEcCtD
Sitaxentan—Skin disorder—Doxorubicin—bone cancer	0.000135	0.000592	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—IL3—bone cancer	0.000135	0.00401	CbGpPWpGaD
Sitaxentan—Somnolence—Epirubicin—bone cancer	0.000133	0.000585	CcSEcCtD
Sitaxentan—Anorexia—Doxorubicin—bone cancer	0.000132	0.000581	CcSEcCtD
Sitaxentan—Feeling abnormal—Methotrexate—bone cancer	0.000132	0.00058	CcSEcCtD
Sitaxentan—Dyspepsia—Epirubicin—bone cancer	0.000132	0.000579	CcSEcCtD
Sitaxentan—Decreased appetite—Epirubicin—bone cancer	0.00013	0.000572	CcSEcCtD
Sitaxentan—Hypotension—Doxorubicin—bone cancer	0.00013	0.000569	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Epirubicin—bone cancer	0.00013	0.000568	CcSEcCtD
Sitaxentan—Fatigue—Epirubicin—bone cancer	0.000129	0.000567	CcSEcCtD
Sitaxentan—Constipation—Epirubicin—bone cancer	0.000128	0.000563	CcSEcCtD
Sitaxentan—Pain—Epirubicin—bone cancer	0.000128	0.000563	CcSEcCtD
Sitaxentan—Urticaria—Methotrexate—bone cancer	0.000127	0.000559	CcSEcCtD
Sitaxentan—Body temperature increased—Methotrexate—bone cancer	0.000127	0.000556	CcSEcCtD
Sitaxentan—Insomnia—Doxorubicin—bone cancer	0.000126	0.000551	CcSEcCtD
Sitaxentan—Feeling abnormal—Epirubicin—bone cancer	0.000124	0.000542	CcSEcCtD
Sitaxentan—Somnolence—Doxorubicin—bone cancer	0.000123	0.000541	CcSEcCtD
Sitaxentan—Dyspepsia—Doxorubicin—bone cancer	0.000122	0.000536	CcSEcCtD
Sitaxentan—Decreased appetite—Doxorubicin—bone cancer	0.000121	0.000529	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Doxorubicin—bone cancer	0.00012	0.000526	CcSEcCtD
Sitaxentan—Fatigue—Doxorubicin—bone cancer	0.00012	0.000525	CcSEcCtD
Sitaxentan—Urticaria—Epirubicin—bone cancer	0.000119	0.000523	CcSEcCtD
Sitaxentan—Pain—Doxorubicin—bone cancer	0.000119	0.000521	CcSEcCtD
Sitaxentan—Constipation—Doxorubicin—bone cancer	0.000119	0.000521	CcSEcCtD
Sitaxentan—Body temperature increased—Epirubicin—bone cancer	0.000119	0.00052	CcSEcCtD
Sitaxentan—Hypersensitivity—Methotrexate—bone cancer	0.000118	0.000518	CcSEcCtD
Sitaxentan—EDNRA—GPCR downstream signaling—GNA11—bone cancer	0.000117	0.00349	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—SMO—bone cancer	0.000116	0.00346	CbGpPWpGaD
Sitaxentan—Asthenia—Methotrexate—bone cancer	0.000115	0.000505	CcSEcCtD
Sitaxentan—Feeling abnormal—Doxorubicin—bone cancer	0.000114	0.000502	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—RGS1—bone cancer	0.000112	0.00335	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—GRM4—bone cancer	0.000112	0.00335	CbGpPWpGaD
Sitaxentan—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	0.000112	0.00333	CbGpPWpGaD
Sitaxentan—Hypersensitivity—Epirubicin—bone cancer	0.000111	0.000485	CcSEcCtD
Sitaxentan—Urticaria—Doxorubicin—bone cancer	0.00011	0.000484	CcSEcCtD
Sitaxentan—Body temperature increased—Doxorubicin—bone cancer	0.00011	0.000481	CcSEcCtD
Sitaxentan—Diarrhoea—Methotrexate—bone cancer	0.00011	0.000481	CcSEcCtD
Sitaxentan—Asthenia—Epirubicin—bone cancer	0.000108	0.000472	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—GNA11—bone cancer	0.000106	0.00317	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—IL3—bone cancer	0.000106	0.00316	CbGpPWpGaD
Sitaxentan—Dizziness—Methotrexate—bone cancer	0.000106	0.000465	CcSEcCtD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	0.000105	0.00312	CbGpPWpGaD
Sitaxentan—Diarrhoea—Epirubicin—bone cancer	0.000103	0.00045	CcSEcCtD
Sitaxentan—Hypersensitivity—Doxorubicin—bone cancer	0.000102	0.000449	CcSEcCtD
Sitaxentan—Vomiting—Methotrexate—bone cancer	0.000102	0.000447	CcSEcCtD
Sitaxentan—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	0.000102	0.00304	CbGpPWpGaD
Sitaxentan—Rash—Methotrexate—bone cancer	0.000101	0.000443	CcSEcCtD
Sitaxentan—Dermatitis—Methotrexate—bone cancer	0.000101	0.000443	CcSEcCtD
Sitaxentan—Headache—Methotrexate—bone cancer	0.0001	0.000441	CcSEcCtD
Sitaxentan—Asthenia—Doxorubicin—bone cancer	9.96e-05	0.000437	CcSEcCtD
Sitaxentan—Dizziness—Epirubicin—bone cancer	9.92e-05	0.000435	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—GRM1—bone cancer	9.74e-05	0.0029	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—IL3—bone cancer	9.63e-05	0.00287	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—SMO—bone cancer	9.59e-05	0.00286	CbGpPWpGaD
Sitaxentan—Vomiting—Epirubicin—bone cancer	9.54e-05	0.000419	CcSEcCtD
Sitaxentan—Nausea—Methotrexate—bone cancer	9.53e-05	0.000418	CcSEcCtD
Sitaxentan—Diarrhoea—Doxorubicin—bone cancer	9.5e-05	0.000417	CcSEcCtD
Sitaxentan—Rash—Epirubicin—bone cancer	9.46e-05	0.000415	CcSEcCtD
Sitaxentan—Dermatitis—Epirubicin—bone cancer	9.45e-05	0.000415	CcSEcCtD
Sitaxentan—Headache—Epirubicin—bone cancer	9.4e-05	0.000412	CcSEcCtD
Sitaxentan—CYP2C19—Biological oxidations—CYP3A4—bone cancer	9.39e-05	0.0028	CbGpPWpGaD
Sitaxentan—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	9.26e-05	0.00276	CbGpPWpGaD
Sitaxentan—Dizziness—Doxorubicin—bone cancer	9.18e-05	0.000403	CcSEcCtD
Sitaxentan—Nausea—Epirubicin—bone cancer	8.91e-05	0.000391	CcSEcCtD
Sitaxentan—Vomiting—Doxorubicin—bone cancer	8.83e-05	0.000387	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—GNA11—bone cancer	8.77e-05	0.00261	CbGpPWpGaD
Sitaxentan—Rash—Doxorubicin—bone cancer	8.76e-05	0.000384	CcSEcCtD
Sitaxentan—Dermatitis—Doxorubicin—bone cancer	8.75e-05	0.000384	CcSEcCtD
Sitaxentan—Headache—Doxorubicin—bone cancer	8.7e-05	0.000382	CcSEcCtD
Sitaxentan—CYP2C9—Biological oxidations—CYP3A4—bone cancer	8.56e-05	0.00255	CbGpPWpGaD
Sitaxentan—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	8.45e-05	0.00252	CbGpPWpGaD
Sitaxentan—Nausea—Doxorubicin—bone cancer	8.25e-05	0.000362	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—ATF1—bone cancer	8.15e-05	0.00243	CbGpPWpGaD
Sitaxentan—CYP2C19—Biological oxidations—GSTP1—bone cancer	8.03e-05	0.00239	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—IL3—bone cancer	7.95e-05	0.00237	CbGpPWpGaD
Sitaxentan—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	7.92e-05	0.00236	CbGpPWpGaD
Sitaxentan—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	7.46e-05	0.00222	CbGpPWpGaD
Sitaxentan—CYP2C9—Biological oxidations—GSTP1—bone cancer	7.32e-05	0.00218	CbGpPWpGaD
Sitaxentan—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	7.22e-05	0.00215	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—SMO—bone cancer	6.86e-05	0.00205	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—TGFBR2—bone cancer	6.8e-05	0.00203	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—IGF1R—bone cancer	6.4e-05	0.00191	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—GNA11—bone cancer	6.28e-05	0.00187	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—ATF1—bone cancer	5.84e-05	0.00174	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—IL3—bone cancer	5.69e-05	0.0017	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—NDUFA12—bone cancer	5.63e-05	0.00168	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—NDUFA12—bone cancer	5.13e-05	0.00153	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—TGFBR2—bone cancer	4.87e-05	0.00145	CbGpPWpGaD
Sitaxentan—CYP3A4—Biological oxidations—GSTP1—bone cancer	4.83e-05	0.00144	CbGpPWpGaD
Sitaxentan—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	4.76e-05	0.00142	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—NT5C3A—bone cancer	4.66e-05	0.00139	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—KIT—bone cancer	4.64e-05	0.00138	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—IGF1R—bone cancer	4.58e-05	0.00136	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—BRAF—bone cancer	4.36e-05	0.0013	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—NT5C3A—bone cancer	4.25e-05	0.00127	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—EGFR—bone cancer	4.23e-05	0.00126	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—MDM2—bone cancer	3.66e-05	0.00109	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—NDUFA12—bone cancer	3.39e-05	0.00101	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—KIT—bone cancer	3.32e-05	0.00099	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—JUN—bone cancer	3.18e-05	0.000947	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—BRAF—bone cancer	3.12e-05	0.00093	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—MMP9—bone cancer	3.09e-05	0.000921	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—EGFR—bone cancer	3.03e-05	0.000902	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—NT5C3A—bone cancer	2.8e-05	0.000836	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—MDM2—bone cancer	2.62e-05	0.00078	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—EGFR—bone cancer	2.5e-05	0.000744	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—JUN—bone cancer	2.27e-05	0.000678	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—MMP9—bone cancer	2.21e-05	0.000659	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—TP53—bone cancer	2.1e-05	0.000625	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ENO2—bone cancer	2.04e-05	0.000609	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—DHFR—bone cancer	1.9e-05	0.000565	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ENO2—bone cancer	1.86e-05	0.000555	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—EGFR—bone cancer	1.79e-05	0.000533	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GNA11—bone cancer	1.77e-05	0.000528	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—DHFR—bone cancer	1.73e-05	0.000515	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GNA11—bone cancer	1.62e-05	0.000481	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CYP3A4—bone cancer	1.61e-05	0.000479	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.6e-05	0.000476	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—TP53—bone cancer	1.5e-05	0.000447	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CYP3A4—bone cancer	1.46e-05	0.000436	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.46e-05	0.000434	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GSTP1—bone cancer	1.37e-05	0.000409	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GSTP1—bone cancer	1.25e-05	0.000373	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ENO2—bone cancer	1.23e-05	0.000366	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—DHFR—bone cancer	1.14e-05	0.00034	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GNA11—bone cancer	1.07e-05	0.000317	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GSTP1—bone cancer	8.26e-06	0.000246	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PTGS2—bone cancer	7.12e-06	0.000212	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PTGS2—bone cancer	6.49e-06	0.000193	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PTGS2—bone cancer	4.28e-06	0.000128	CbGpPWpGaD
